Safety information on this page is drawn from published clinical trial data and should not be used as personal medical guidance. Consult your physician or pharmacist before starting any supplement.
Overview of Safety Profile
Boswellia serrata extracts have generally been reported as well-tolerated in published short-term clinical trials, with gastrointestinal discomfort as the most commonly noted adverse effect. However, most trials ran for 8–12 weeks and sample sizes were small. Absence of reported serious adverse effects in small short-term trials should not be interpreted as confirmation of long-term safety.
Commonly Reported Adverse Effects
Gastrointestinal Effects
The most consistently reported adverse effects in clinical trials are gastrointestinal in nature, including nausea, abdominal discomfort, loose stools, and diarrhea. These effects have generally been described as mild and transient. Taking Boswellia supplements with food may reduce gastrointestinal discomfort.
Skin Reactions
Occasional skin reactions, including rash and pruritus, have been reported in some trials at low frequency. Individuals with known allergies to plants in the Burseraceae family should exercise caution.
Headache
Headache has been reported infrequently across trials. A causal relationship to Boswellia supplementation has not been established in these reports.
Long-term Safety
Controlled safety data beyond 12 weeks are limited. The majority of published trials ran for 8–12 weeks. In general, long-term safety of Boswellia serrata supplementation has not been adequately studied in controlled settings.
Drug Interactions
In laboratory studies, boswellic acids have been identified as potential modulators of drug-metabolizing enzymes (particularly CYP450 enzymes) and membrane transport proteins (OATP1B3 and MRP2). The clinical significance of these interactions has not been established. Populations requiring particular caution include those taking anticoagulants (warfarin, apixaban, rivaroxaban), immunosuppressants (cyclosporine, tacrolimus), statins, or any medication with a narrow therapeutic window. See the Drug Interactions page for more detail.
Special Populations
Pregnancy and Breastfeeding
Safety in pregnancy and breastfeeding has not been established in clinical trials. Avoid use during pregnancy or breastfeeding without explicit guidance from a healthcare provider.
Pre-surgical Considerations
Discuss supplement use with your surgical team before any planned procedure. Most guidelines recommend discontinuing herbal supplements 2 weeks before elective surgery.
Children
Clinical trial data in pediatric populations is absent. Safety and appropriate dosing for children have not been established.